- Ticker
- ACST
- Price
- 0.71
- Stock movement down
- -0.02 (-2.73%)
- Company name
- Acasti Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 31.68M
- Ent value
- 17.50M
- Price/Sales
- 2436.89
- Price/Book
- 0.32
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -36.60%
- 3 year return
- -50.23%
- 5 year return
- -40.30%
- 10 year return
- -43.11%
Last updated: 2023-01-31
DIVIDENDS
ACST does not pay dividends
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2436.89 |
| Price to Book | 0.32 |
| EV to Sales | 1346.20 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 44.61M |
| EPS (TTM) | -0.37 |
| FCF per share (TTM) | -0.32 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 13.00K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -18.39M |
| Net income (TTM) | -16.52M |
| EPS (TTM) | -0.37 |
| EPS (1y forward) | -0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -141446.15% |
| Profit margin (TTM) | -127038.46% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.93M |
| Net receivables | 859.00K |
| Total current assets | 37.51M |
| Goodwill | 12.96M |
| Intangible assets | 69.81M |
| Property, plant and equipment | 0.00 |
| Total assets | 120.91M |
| Accounts payable | 3.73M |
| Short/Current long term debt | 520.00K |
| Total current liabilities | 3.81M |
| Total liabilities | 20.75M |
| Shareholder's equity | 100.16M |
| Net tangible assets | 17.39M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.31M |
| Capital expenditures (TTM) | 23.00K |
| Free cash flow (TTM) | -14.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -16.49% |
| Return on Assets | -13.66% |
| Return on Invested Capital | -16.48% |
| Cash Return on Invested Capital | -14.29% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.74 |
| Daily high | 0.75 |
| Daily low | 0.68 |
| Daily Volume | 116K |
| All-time high | 325.60 |
| 1y analyst estimate | 2.26 |
| Beta | 1.10 |
| EPS (TTM) | -0.37 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 Feb 2023 |
Downside potential
Loading...
Downside potential data
| ACST | S&P500 | |
| Current price drop from All-time high | -99.78% | -14.91% |
| Highest price drop | -99.90% | -56.47% |
| Date of highest drop | 12 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -84.92% | -11.49% |
| Avg time to new high | 75 days | 13 days |
| Max time to new high | 2380 days | 1805 days |
COMPANY DETAILS
Marketcap
31.68M
Marketcap category
Small-cap
Description
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Janelle D'Alvise
Country
USA
City
Laval
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 25, 2023
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 24, 2023
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
January 17, 2023
Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage specialty pharma company with drug delivery technologies and dru...
January 17, 2023
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 13, 2023
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
January 5, 2023
Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript November 14, 2022 Operator: Good day, and welcome to the Acasti Pharma Second Quarter 2023 Earnings Event Call. All participants will ...
December 29, 2022
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
December 28, 2022
LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage dr...
December 22, 2022
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, special...
November 14, 2022
Next page